Heterocyclic modulators of lipid synthesis
US-2024400552-A1 · Dec 5, 2024 · US
N-substituted 4-aminoquinazoline derivatives and methods of use
US10273229B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10273229-B2 |
| Application number | US-201515504120-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 27, 2015 |
| Priority date | Aug 28, 2014 |
| Publication date | Apr 30, 2019 |
| Grant date | Apr 30, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides kinase inhibitor analogs with improved properties, such as improved efficacy, pharmacokinetics, safety, and specificity. In some embodiments, the present invention provides lapatinib analogs that provide therapeutic benefits.
First claim
Opening claim text (preview).
We claim: 1. A method for producing an improved kinase inhibitor analog comprising exposing a starting kinase inhibitor to a cytochrome P450 monooxygenase to produce an analog, purifying said analog, and determining the kinase inhibition activity of said analog, wherein the kinase inhibition activity of said analog is determined against a kinase comprising EGFR, ErbB2, ErbB4, or Syk. 2. The method of claim 1 , wherein said kinase inhibitor analog comprises an introduced hydroxyl moiety. 3. The method of claim 1 , wherein said kinase inhibitor analog is further modified to provide additional kinase inhibitors. 4. The method of claim 2 , wherein the site of hydroxylation is further modified chemically to provide new kinase inhibitors. 5. The method of claim 1 , wherein the starting kinase inhibitor is lapatinib.
Assignees
Inventors
Classifications
Heterorings having nitrogen atoms as the only ring heteroatoms · CPC title
cell-free systems · CPC title
Phosphotransferases in general · CPC title
Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A) · CPC title
Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10273229B2 cover?
- The present invention provides kinase inhibitor analogs with improved properties, such as improved efficacy, pharmacokinetics, safety, and specificity. In some embodiments, the present invention provides lapatinib analogs that provide therapeutic benefits.
- Who is the assignee on this patent?
- Codexis Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D405/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).